Valvular & structural heart disease
Prevalence, progression, and clinical outcomes of mitral valve prolapse: a systematic review and meta-analysis
Authors' conclusion
MVP is common, with greater prevalence in syndromes. Although more common with age, MVP is observed in infants. MVP related MR is progressive, especially in moderate MR, and there is a signal of excess mortality for unclear reasons. Valve services must manage the whole life journey and the potential risks associated with MVP.
Study context
- Population
- General population, patients with associated syndromes, and different age groups (neonates, children, adolescents and adults) with mitral valve prolapse83 studies · non-syndrome associated (47 studies) 992,944 · syndrome associated (31 studies) 3,067 · mitral regurgitation (MR) progression or adverse outcomes (5 studies) 1,287
- Outcome
- Prevalence of MVP
Pooled result
As reported in the abstract
Further pooled results
Prevalence of MVP, older vs young adults · significantly higher in older adults
P = 0.01
Age-stratified prevalence of mitral valve prolapse (MVP)
- Age-stratified prevalence in neonates, children, adolescents and adults, respectively
- 0.5, 1.8, 2.7, and 2.0%
- No significant difference across ages (meta-regression and subgroup analysis)
- P = 0.81
Prevalence of MVP in genetic syndromes
- Prevalence rates markedly higher in patients with genetic syndromes
MR progression
- MR progressed, overall
- 5.5 per 100 person-years
Adverse outcomes
Per 100 person-years
- All-cause mortality
- 1.7
- Development of heart failure
- 1.0
- Need for mitral valve intervention
- 1.2
Original publication
Prevalence, progression, and clinical outcomes of mitral valve prolapse: a systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. Published 28 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →